Consolidated Statement Of Income

BrightPath Biotherapeutics Co., Ltd. - Filing #7580403

Concept 2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2020-04-01 to
2021-03-31
2019-04-01 to
2020-03-31
2019-04-01 to
2020-03-31
2019-04-01 to
2020-03-31
2019-04-01 to
2020-03-31
Consolidated statement of income
Statement of income
Net sales
2,504,000 JPY
11,300,000 JPY
Cost of sales
1,145,000 JPY
4,467,000 JPY
Operating expenses
Operating expenses - general
Remuneration for directors (and other officers)
51,550,000 JPY
58,300,000 JPY
Depreciation
22,000 JPY
177,000 JPY
Operating expenses
Selling, general and administrative expenses
1,734,161,000 JPY
1,834,182,000 JPY
Operating expenses
Ordinary profit (loss)
-1,738,636,000 JPY
-1,823,996,000 JPY
General and administrative expenses
Salaries
Operating profit (loss)
-1,732,802,000 JPY
-1,827,349,000 JPY
Operating expenses
Research and development expenses
1,408,443,000 JPY
1,484,854,000 JPY
Gross profit (loss)
1,358,000 JPY
6,832,000 JPY
Net sales
Non-operating income
Interest income
35,000 JPY
42,000 JPY
Other
98,000 JPY
357,000 JPY
Non-operating income
3,265,000 JPY
3,409,000 JPY
Cost of sales
Selling, general and administrative expenses
Extraordinary income
31,051,000 JPY
12,550,000 JPY
Non-operating expenses
Non-operating expenses
9,099,000 JPY
56,000 JPY
Share issuance costs
9,099,000 JPY
JPY
Extraordinary losses
9,629,000 JPY
48,415,000 JPY
Impairment losses
9,629,000 JPY
48,159,000 JPY
Other
0 JPY
JPY
Profit (loss) before income taxes
-1,717,214,000 JPY
-1,859,861,000 JPY
Gross profit
Extraordinary income
Gain on sale of non-current assets
JPY
95,000 JPY
Income taxes - current
2,420,000 JPY
2,732,000 JPY
Extraordinary losses
Loss on sale of non-current assets
JPY
255,000 JPY
Income taxes - deferred
JPY
-4,819,000 JPY
Income taxes
2,420,000 JPY
-2,087,000 JPY
Profit (loss)
-1,719,634,000 JPY
-1,719,634,000 JPY
-1,719,634,000 JPY
-1,719,634,000 JPY
-1,857,774,000 JPY
-1,857,774,000 JPY
-1,857,774,000 JPY
-1,857,774,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.